Regorafenib, a small-molecule inhibitor of multiple receptor tyrosine kinases, is utilized as a second-line treatment for metastatic tumors.<h4>Methods</h4>Bioinformatics analysis and clinical analysis of 14 breast cancer cases revealed the EGFR expression and activation in tumor tissues. This evidence concerns the gene EGFR and metastatic neoplasm.